Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA.

Belliveau NM, Huft J, Lin PJ, Chen S, Leung AK, Leaver TJ, Wild AW, Lee JB, Taylor RJ, Tam YK, Hansen CL, Cullis PR.

Mol Ther Nucleic Acids. 2012 Aug 14;1:e37. doi: 10.1038/mtna.2012.28.

2.

Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core.

Leung AK, Hafez IM, Baoukina S, Belliveau NM, Zhigaltsev IV, Afshinmanesh E, Tieleman DP, Hansen CL, Hope MJ, Cullis PR.

J Phys Chem C Nanomater Interfaces. 2012 Aug 30;116(34):18440-18450. Epub 2012 Jul 18.

3.

Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing.

Zhigaltsev IV, Belliveau N, Hafez I, Leung AK, Huft J, Hansen C, Cullis PR.

Langmuir. 2012 Feb 21;28(7):3633-40. doi: 10.1021/la204833h. Epub 2012 Feb 9.

PMID:
22268499
4.

Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems.

Leung AK, Tam YY, Chen S, Hafez IM, Cullis PR.

J Phys Chem B. 2015 Jul 16;119(28):8698-706. doi: 10.1021/acs.jpcb.5b02891. Epub 2015 Jul 7.

PMID:
26087393
5.

Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation.

Chen D, Love KT, Chen Y, Eltoukhy AA, Kastrup C, Sahay G, Jeon A, Dong Y, Whitehead KA, Anderson DG.

J Am Chem Soc. 2012 Apr 25;134(16):6948-51. doi: 10.1021/ja301621z. Epub 2012 Apr 10.

PMID:
22475086
6.

Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.

Chen S, Tam YY, Lin PJ, Leung AK, Tam YK, Cullis PR.

J Control Release. 2014 Dec 28;196:106-12. doi: 10.1016/j.jconrel.2014.09.025. Epub 2014 Oct 5.

PMID:
25285610
7.

Assessing the heterogeneity level in lipid nanoparticles for siRNA delivery: size-based separation, compositional heterogeneity, and impact on bioperformance.

Zhang J, Pei Y, Zhang H, Wang L, Arrington L, Zhang Y, Glass A, Leone AM.

Mol Pharm. 2013 Jan 7;10(1):397-405. doi: 10.1021/mp3005337. Epub 2012 Dec 19.

PMID:
23210488
8.

Lipid nanoparticle delivery systems for siRNA-based therapeutics.

Wan C, Allen TM, Cullis PR.

Drug Deliv Transl Res. 2014 Feb;4(1):74-83. doi: 10.1007/s13346-013-0161-z.

PMID:
25786618
9.

Microfluidic-based manufacture of siRNA-lipid nanoparticles for therapeutic applications.

Walsh C, Ou K, Belliveau NM, Leaver TJ, Wild AW, Huft J, Lin PJ, Chen S, Leung AK, Lee JB, Hansen CL, Taylor RJ, Ramsay EC, Cullis PR.

Methods Mol Biol. 2014;1141:109-20. doi: 10.1007/978-1-4939-0363-4_6.

PMID:
24567134
10.

Polydispersity characterization of lipid nanoparticles for siRNA delivery using multiple detection size-exclusion chromatography.

Zhang J, Haas RM, Leone AM.

Anal Chem. 2012 Jul 17;84(14):6088-96. doi: 10.1021/ac3007768. Epub 2012 Jul 2.

PMID:
22816783
11.

Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.

Chen S, Tam YY, Lin PJ, Sung MM, Tam YK, Cullis PR.

J Control Release. 2016 Aug 10;235:236-44. doi: 10.1016/j.jconrel.2016.05.059. Epub 2016 May 26.

PMID:
27238441
12.

Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA.

Spagnou S, Miller AD, Keller M.

Biochemistry. 2004 Oct 26;43(42):13348-56.

PMID:
15491141
13.

Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA.

Lin PJ, Tam YY, Hafez I, Sandhu A, Chen S, Ciufolini MA, Nabi IR, Cullis PR.

Nanomedicine. 2013 Feb;9(2):233-46. doi: 10.1016/j.nano.2012.05.019. Epub 2012 Jun 12.

PMID:
22698807
14.

Efficient down-regulation of CDK4 by novel lipid nanoparticle-mediated siRNA delivery.

Wang X, Yu B, Wu Y, Lee RJ, Lee LJ.

Anticancer Res. 2011 May;31(5):1619-26.

PMID:
21617218
15.

Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA.

Tam YY, Chen S, Zaifman J, Tam YK, Lin PJ, Ansell S, Roberge M, Ciufolini MA, Cullis PR.

Nanomedicine. 2013 Jul;9(5):665-74. doi: 10.1016/j.nano.2012.11.006. Epub 2012 Dec 6.

PMID:
23219877
16.

Advances in Lipid Nanoparticles for siRNA Delivery.

Tam YY, Chen S, Cullis PR.

Pharmaceutics. 2013 Sep 18;5(3):498-507. doi: 10.3390/pharmaceutics5030498.

17.

Elucidation of the physicochemical properties and potency of siRNA-loaded small-sized lipid nanoparticles for siRNA delivery.

Sato Y, Note Y, Maeki M, Kaji N, Baba Y, Tokeshi M, Harashima H.

J Control Release. 2016 May 10;229:48-57. doi: 10.1016/j.jconrel.2016.03.019. Epub 2016 Mar 17.

PMID:
26995758
18.

Production of limit size nanoliposomal systems with potential utility as ultra-small drug delivery agents.

Zhigaltsev IV, Tam YK, Leung AK, Cullis PR.

J Liposome Res. 2016;26(2):96-102. doi: 10.3109/08982104.2015.1025411. Epub 2015 Apr 9.

PMID:
25856305
19.

Physicochemical characterization techniques for lipid based delivery systems for siRNA.

Kapoor M, Burgess DJ, Patil SD.

Int J Pharm. 2012 May 1;427(1):35-57. doi: 10.1016/j.ijpharm.2011.09.032. Epub 2011 Sep 29. Review.

PMID:
21979250
20.

Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA.

Jensen DK, Jensen LB, Koocheki S, Bengtson L, Cun D, Nielsen HM, Foged C.

J Control Release. 2012 Jan 10;157(1):141-8. doi: 10.1016/j.jconrel.2011.08.011. Epub 2011 Aug 12.

PMID:
21864597
Items per page

Supplemental Content

Write to the Help Desk